AR and non-small cell lung carcinoma: Dihydrotestosterone (DHT, AR activator) induces the expression of ACE2 and TMPRSS2 in activin-sensitive prostate cancer cells (LNCaP) and A549 non-small cell lung cancer cells, and GT0918 (a new generation of AR antagonists) can inhibit DHT-induced expression of ACE2 and TMPRSS2 [40].